{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:00:07Z","timestamp":1792144807473,"version":"4.4.0"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473544"],"award-info":[{"award-number":["82473544"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404168"],"award-info":[{"award-number":["82404168"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.critrevonc.2025.104808","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T19:36:46Z","timestamp":1749843406000},"page":"104808","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["T cell-mediated mechanisms of immune-related adverse events induced by immune checkpoint inhibitors"],"prefix":"10.1016","volume":"213","author":[{"given":"Lintong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruzeng","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guomin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuping","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104808_bib1","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1001\/jamaophthalmol.2018.1851","article-title":"Birdshot-like chorioretinopathy associated with pembrolizumab treatment","volume":"136","author":"Acaba-Berrocal","year":"2018","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.critrevonc.2025.104808_bib2","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","article-title":"T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis","volume":"611","author":"Axelrod","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104808_bib3","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/07357907.2017.1324032","article-title":"Immunological characteristics of colitis associated with Anti-CTLA-4 antibody therapy","volume":"35","author":"Bamias","year":"2017","journal-title":"Cancer Invest"},{"key":"10.1016\/j.critrevonc.2025.104808_bib4","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","article-title":"Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4","volume":"24","author":"Beck","year":"2006","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104808_bib5","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of checkpoint Inhibitor-Induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2025.104808_bib6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/imr.13258","article-title":"Autoimmunity in immune checkpoint inhibitor-induced immune-related adverse events: a focus on autoimmune skin toxicity and pneumonitis","volume":"318","author":"Berner","year":"2023","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.critrevonc.2025.104808_bib7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/imr.13262","article-title":"Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responses","volume":"318","author":"Blum","year":"2023","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.critrevonc.2025.104808_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104808_bib9","article-title":"Single-cell RNA sequencing reveals distinct t cell populations in immune-related adverse events of checkpoint inhibitors","volume":"4","author":"Bukhari","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.critrevonc.2025.104808_bib10","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20192179","article-title":"Understanding adverse events of immunotherapy: a mechanistic perspective","volume":"218","author":"Burke","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.critrevonc.2025.104808_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1197630","article-title":"Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy","volume":"14","author":"Carbone","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104808_bib12","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1038\/s41598-022-09373-9","article-title":"Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients","volume":"12","author":"Carbone","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2025.104808_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54180-7","article-title":"Immune checkpoint inhibitor-induced severe epidermal necrolysis mediated by macrophage-derived CXCL10 and abated by TNF blockade","volume":"15","author":"Chen","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2025.104808_bib14","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.cell.2024.03.037","article-title":"Principles and therapeutic applications of adaptive immunity","volume":"187","author":"Chi","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2025.104808_bib15","first-page":"426","article-title":"Liver biopsy findings in patients on immune checkpoint inhibitors","volume":"34","author":"Cohen","year":"2021","journal-title":"Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc."},{"key":"10.1016\/j.critrevonc.2025.104808_bib16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00417-017-3835-2","article-title":"Checkpoint inhibitor-induced uveitis: a case series","volume":"256","author":"Conrady","year":"2018","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol. Albrecht Von. Graefes Arch. Klin. Exp. Ophthalmol."},{"key":"10.1016\/j.critrevonc.2025.104808_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002642","article-title":"Evaluating T-cell cross-reactivity between tumors and immune-related adverse events with TCR sequencing: pitfalls in interpretations of functional relevance","volume":"9","author":"Cottrell","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104808_bib18","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1001\/archderm.1995.01690150078015","article-title":"Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells","volume":"131","author":"Cui","year":"1995","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.critrevonc.2025.104808_bib19","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1080\/1744666X.2023.2221434","article-title":"Updates in toxicities associated with immune checkpoint inhibitors","volume":"19","author":"Curkovic","year":"2023","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104808_bib20","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/cup.13454","article-title":"Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14+ and CD16+ monocytes driving an innate immune response","volume":"46","author":"Curry","year":"2019","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.critrevonc.2025.104808_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.955038","article-title":"Induction of T cell exhaustion by JAK1\/3 inhibition in the treatment of alopecia areata","volume":"13","author":"Dai","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104808_bib22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41586-023-06217-y","article-title":"PD-1 maintains CD8 T cell tolerance towards cutaneous neoantigens","volume":"619","author":"Damo","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104808_bib23","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1158\/2326-6066.CIR-13-0016","article-title":"Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production","volume":"1","author":"de Coa\u00f1a","year":"2013","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2025.104808_bib24","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.cell.2021.02.011","article-title":"Understanding and treating the inflammatory adverse events of cancer immunotherapy","volume":"184","author":"Dougan","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2025.104808_bib25","article-title":"Multiple evanescent White dot syndrome-like reaction associated with ipilimumab and nivolumab immune checkpoint inhibitor therapy for metastasis of choroidal melanoma","volume":"25","author":"Duong","year":"2022","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"10.1016\/j.critrevonc.2025.104808_bib26","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMc1703047","article-title":"Reversal of autoimmune toxicity and loss of tumor response by Interleukin-17 blockade","volume":"376","author":"Esfahani","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104808_bib27","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.critrevonc.2025.104808_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.866703","article-title":"Networks of CD8+ T cell response activation in melanoma and vitiligo","volume":"13","author":"Fukuda","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104808_bib29","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/bjd.18379","article-title":"Decline of programmed death-1-positive circulating T regulatory cells predicts more favourable clinical outcome of patients with melanoma under immune checkpoint blockade","volume":"182","author":"Gambichler","year":"2020","journal-title":"Br. J. Dermatol."},{"issue":"41","key":"10.1016\/j.critrevonc.2025.104808_bib30","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/CJI.0000000000000191","article-title":"Acute flare of bullous pemphigus with pembrolizumab used for treatment of metastatic urothelial cancer","volume":"1997","author":"Garje","year":"2018","journal-title":"J. Immunother. Hagerstown Md"},{"key":"10.1016\/j.critrevonc.2025.104808_bib31","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s11912-022-01279-z","article-title":"Paraneoplastic neurological syndromes: transitioning between the old and the new","volume":"24","author":"Gastaldi","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2025.104808_bib32","doi-asserted-by":"crossref","DOI":"10.1172\/JCI170503","article-title":"Pulmonary toxicity of immune checkpoint immunotherapy","volume":"134","author":"Ghanbar","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2025.104808_bib33","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.3389\/fimmu.2018.02374","article-title":"Inhibitory receptors and pathways of lymphocytes: the role of PD-1 in treg development and their involvement in autoimmunity onset and cancer progression","volume":"9","author":"Gianchecchi","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104808_bib34","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1158\/2326-6066.CIR-20-0969","article-title":"Regulatory T-cell transcriptomic reprogramming characterizes adverse events by checkpoint inhibitors in solid tumors","volume":"9","author":"Grigoriou","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2025.104808_bib35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/bjd\/ljad324","article-title":"Targeting interleukin (IL)-4\/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy","volume":"190","author":"Guerrero-Juarez","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.critrevonc.2025.104808_bib36","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"ESMO guidelines committee. Electronic address: clinicalguidelines@esmo.org. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104808_bib37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2024.12.028","article-title":"Pathogenic mechanisms of immune checkpoint inhibitor (ICI)-Associated retinal and choroidal adverse reactions","volume":"272","author":"Haliyur","year":"2025","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.critrevonc.2025.104808_bib38","first-page":"1","article-title":"The diverse roles of the TNF axis in cancer progression and metastasis","volume":"11","author":"Ham","year":"2016","journal-title":"Trends Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104808_bib39","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/s43018-021-00180-1","article-title":"Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy","volume":"2","author":"Han","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104808_bib40","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2200348119","article-title":"Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota","volume":"119","author":"Hu","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2025.104808_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1197364","article-title":"Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases","volume":"14","author":"Ibis","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104808_bib42","doi-asserted-by":"crossref","first-page":"vii17","DOI":"10.1093\/rheumatology\/kez465","article-title":"Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors","volume":"58","author":"Ibraheim","year":"2019","journal-title":"Rheumatol. Oxf. Engl."},{"key":"10.1016\/j.critrevonc.2025.104808_bib43","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2025.104808_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.606056","article-title":"Pembrolizumab-Induced thyroiditis shows PD-L1Expressing histiocytes and infiltrating T cells in thyroid tissue - a case report","volume":"12","author":"Jabkowski","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104808_bib45","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/2326-6066.CIR-18-0682","article-title":"IL17A blockade successfully treated psoriasiform dermatologic toxicity from immunotherapy","volume":"7","author":"Johnson","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2025.104808_bib46","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104808_bib47","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s13691-024-00676-4","article-title":"PD-L1 expression in keratinocyte and infiltration of CD4+ T lymphocyte can predict a severe type of erythema multiforme major induced by the anti-PD-1 antibody, pembrolizumab","volume":"13","author":"Kadoi","year":"2024","journal-title":"Int. Cancer Conf. J."},{"key":"10.1016\/j.critrevonc.2025.104808_bib48","doi-asserted-by":"crossref","first-page":"98.52","DOI":"10.4049\/jimmunol.206.Supp.98.52","article-title":"Myosin specific TRM cells mediate increased severity of immune checkpoint inhibitor myocarditis","volume":"206","author":"Kalinoski","year":"2021","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104808_bib49","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2337\/db22-0557","article-title":"Inflammatory cell infiltration into islets without PD-L1 expression is associated with the development of immune checkpoint Inhibitor-Related type 1 diabetes in genetically susceptible patients","volume":"72","author":"Kawata","year":"2023","journal-title":"Diabetes"},{"key":"10.1016\/j.critrevonc.2025.104808_bib50","first-page":"5278","article-title":"Spontaneous colitis occurrence in transgenic mice with altered B7-mediated costimulation","volume":"181","author":"Kim","year":"2008","journal-title":"J. Immunol. Baltim. Md 1950"},{"key":"10.1016\/j.critrevonc.2025.104808_bib51","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1722023","article-title":"Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment","volume":"9","author":"Kim","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2025.104808_bib52","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41467-022-29539-3","article-title":"Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy","volume":"13","author":"Kim","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2025.104808_bib53","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41467-022-29539-3","article-title":"Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy","volume":"13","author":"Kim","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2025.104808_bib54","doi-asserted-by":"crossref","first-page":"E2383","DOI":"10.1073\/pnas.1603892113","article-title":"Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood","volume":"113","author":"Klocke","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2025.104808_bib55","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008056","article-title":"Lower frequencies of circulating suppressive regulatory t cells and higher frequencies of CD4+ na\u00efve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma","volume":"12","author":"Kovacsovics-Bankowski","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104808_bib56","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1126\/science.1255904","article-title":"Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4","volume":"345","author":"Kuehn","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2025.104808_bib57","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1158\/1078-0432.CCR-23-3431","article-title":"Immunologic profiling of immune-related cutaneous adverse events with checkpoint inhibitors reveals polarized actionable pathways","volume":"30","author":"Lacouture","year":"2024","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104808_bib58","first-page":"696","article-title":"Inhibition of IL-17A protects against thyroid Immune-related adverse events while preserving checkpoint inhibitor anti-tumor efficacy","volume":"209","author":"Lechner","year":"2022","journal-title":"J. Immunol. Baltim. Md 1950"},{"key":"10.1016\/j.critrevonc.2025.104808_bib59","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/14740338.2021.1915279","article-title":"Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion","volume":"20","author":"Lommerts","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.critrevonc.2025.104808_bib60","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1007\/s10620-009-0839-8","article-title":"Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ t cells","volume":"55","author":"Lord","year":"2010","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.critrevonc.2025.104808_bib61","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41591-021-01623-z","article-title":"T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma","volume":"28","author":"Lozano","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2025.104808_bib62","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.cell.2020.06.001","article-title":"Molecular pathways of colon inflammation induced by cancer immunotherapy","volume":"182","author":"Luoma","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2025.104808_bib63","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/ecco-jcc\/jjv227","article-title":"Cancer immunotherapy with Anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease","volume":"10","author":"Marthey","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.critrevonc.2025.104808_bib64","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002261","article-title":"Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer","volume":"9","author":"Maslov","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104808_bib65","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/bjd\/ljad236","article-title":"New insights into programmed cell death protein 1 blockade-associated cutaneous immune-related adverse events","volume":"189","author":"Micevic","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.critrevonc.2025.104808_bib66","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/imr.12721","article-title":"What did we learn from CTLA-4 insufficiency on the human immune system?","volume":"287","author":"Mitsuiki","year":"2019","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.critrevonc.2025.104808_bib67","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2025.104808_bib68","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/neuonc\/noad198","article-title":"Immune signatures of checkpoint inhibitor-induced autoimmunity\u2014a focus on neurotoxicity","volume":"26","author":"M\u00fcller-Jensen","year":"2024","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.critrevonc.2025.104808_bib69","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a037929","article-title":"Memory T-cell heterogeneity and terminology","volume":"13","author":"Muroyama","year":"2021","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.critrevonc.2025.104808_bib70","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2025.104808_bib71","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.autrev.2013.12.004","article-title":"Th17 and regulatory t cell balance in autoimmune and inflammatory diseases","volume":"13","author":"Noack","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.critrevonc.2025.104808_bib72","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41586-024-08061-0","article-title":"Spatial proteomics identifies JAKi as treatment for a lethal skin disease","volume":"635","author":"Nordmann","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104808_bib73","first-page":"113","article-title":"Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors","volume":"4","author":"Nu\u00f1ez","year":"2023","journal-title":"Med N. Y. N."},{"key":"10.1016\/j.critrevonc.2025.104808_bib74","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41582-024-01001-6","article-title":"Peripheral nervous system immune-related adverse events due to checkpoint inhibition","volume":"20","author":"O\u2019Hare","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.critrevonc.2025.104808_bib75","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.it.2019.04.002","article-title":"Adverse events following cancer immunotherapy: obstacles and opportunities","volume":"40","author":"Pauken","year":"2019","journal-title":"Trends Immunol."},{"key":"10.1016\/j.critrevonc.2025.104808_bib76","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.156330","article-title":"Immune cells and their inflammatory mediators modify \u03b2 cells and cause checkpoint inhibitor-induced diabetes","volume":"7","author":"Perdigoto","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.critrevonc.2025.104808_bib77","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3390\/cancers12030546","article-title":"Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"12","author":"Petrelli","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104808_bib78","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1200\/JCO.18.02141","article-title":"Treatment outcomes of immune-related cutaneous adverse events","volume":"37","author":"Phillips","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104808_bib79","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1158\/2326-6066.CIR-22-0362","article-title":"Checkpoint blockade\u2013induced dermatitis and colitis are dominated by tissue-resident memory t cells and Th1\/Tc1 cytokines","volume":"10","author":"Reschke","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2025.104808_bib80","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1053\/j.gastro.2021.06.025","article-title":"Interferon-gamma-producing CD8+ tissue resident memory t cells are a targetable hallmark of immune checkpoint inhibitor-colitis","volume":"161","author":"Sasson","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.critrevonc.2025.104808_bib81","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104808_bib82","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/imr.13243","article-title":"Immunological mechanisms underlying clinical phenotypes and noninvasive diagnosis of immune checkpoint inhibitor-induced kidney disease","volume":"318","author":"Seethapathy","year":"2023","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.critrevonc.2025.104808_bib83","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s12328-020-01317-y","article-title":"A case with hepatic immune-related adverse events caused by nivolumab exhibiting impaired accumulation of regulatory T cells","volume":"14","author":"Sekai","year":"2021","journal-title":"Clin. J. Gastroenterol."},{"key":"10.1016\/j.critrevonc.2025.104808_bib84","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/bjd\/ljad149","article-title":"Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment","volume":"189","author":"Shipman","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.critrevonc.2025.104808_bib85","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.critrevonc.2025.104808_bib86","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/imr.13247","article-title":"Immune-related adverse events after immune check point inhibitors: understanding the intersection with autoimmunity","volume":"318","author":"Singh","year":"2023","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.critrevonc.2025.104808_bib87","doi-asserted-by":"crossref","first-page":"11919","DOI":"10.1073\/pnas.1611421113","article-title":"Clonal expansion of CD8 t cells in the systemic circulation precedes development of ipilimumab-induced toxicities","volume":"113","author":"Subudhi","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2025.104808_bib88","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41573-021-00259-5","article-title":"Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies","volume":"21","author":"Sullivan","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.critrevonc.2025.104808_bib89","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41573-021-00259-5","article-title":"Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies","volume":"21","author":"Sullivan","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.critrevonc.2025.104808_bib90","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1172\/JCI128654","article-title":"The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis","volume":"129","author":"Suresh","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2025.104808_bib91","doi-asserted-by":"crossref","first-page":"124","DOI":"10.5415\/apallergy.0000000000000146","article-title":"From tumor to tolerance: a comprehensive review of immune checkpoint inhibitors and immune-related adverse events","volume":"14","author":"Sutanto","year":"2024","journal-title":"Asia Pac. Allergy"},{"key":"10.1016\/j.critrevonc.2025.104808_bib92","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0165-5728(03)00078-X","article-title":"Autoreactive T cells to the P3A+ isoform of AChR alpha subunit in myasthenia gravis","volume":"137","author":"Suzuki","year":"2003","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.critrevonc.2025.104808_bib93","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10620-022-07598-2","article-title":"CD8+ lymphocyte infiltration is a specific feature of colitis induced by immune checkpoint inhibitors","volume":"68","author":"Takahashi","year":"2023","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.critrevonc.2025.104808_bib94","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/cr.2016.151","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Tanaka","year":"2017","journal-title":"Cell Res."},{"key":"10.1016\/j.critrevonc.2025.104808_bib95","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40425-015-0081-1","article-title":"Baseline circulating IL-17 predicts toxicity while TGF-\u03b21 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma","volume":"3","author":"Tarhini","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104808_bib96","doi-asserted-by":"crossref","first-page":"6805","DOI":"10.3390\/curroncol30070498","article-title":"Molecular mechanisms of cutaneous Immune-Related adverse events (irAEs) induced by immune checkpoint inhibitors","volume":"30","author":"Teng","year":"2023","journal-title":"Curr. Oncol. Tor. Ont."},{"key":"10.1016\/j.critrevonc.2025.104808_bib97","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2025.104808_bib98","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/cup.12876","article-title":"Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy","volume":"44","author":"Vivar","year":"2017","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.critrevonc.2025.104808_bib99","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1479-5876-7-35","article-title":"CTLA4 blockade increases Th17 cells in patients with metastatic melanoma","volume":"7","author":"von Euw","year":"2009","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2025.104808_bib100","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.1007\/s00432-023-04696-0","article-title":"Characterization of immunomodulatory factors and cells in bronchoalveolar lavage fluid for immune checkpoint inhibitor-related pneumonitis","volume":"149","author":"Wang","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104808_bib101","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-Related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2025.104808_bib102","first-page":"89","article-title":"Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma","volume":"35","author":"Weber","year":"2012","journal-title":"J. Immunother. Hagerstown Md 1997"},{"key":"10.1016\/j.critrevonc.2025.104808_bib103","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.768957","article-title":"Mechanisms of immune checkpoint inhibitor-mediated colitis","volume":"12","author":"Westdorp","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104808_bib104","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104808_bib105","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ijc.34940","article-title":"Tissue-resident memory T cells in immunotherapy and immune-related adverse events by immune checkpoint inhibitor","volume":"155","author":"Xiong","year":"2024","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104808_bib106","article-title":"Immune-related adverse events of checkpoint inhibitors: insights into immunological dysregulation","volume":"213","author":"Yang","year":"2020","journal-title":"Clin. Immunol. Orlando Fla"},{"key":"10.1016\/j.critrevonc.2025.104808_bib107","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00130832-200108000-00004","article-title":"Immunohistology of drug-induced exanthema: clues to pathogenesis","volume":"1","author":"Yawalkar","year":"2001","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104808_bib108","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/ITT.S126227","article-title":"Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review","volume":"6","author":"Yoest","year":"2017","journal-title":"ImmunoTargets Ther."},{"key":"10.1016\/j.critrevonc.2025.104808_bib109","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/cvr\/cvae133","article-title":"Central memory CD4+ T cells play a protective role against immune checkpoint inhibitor-associated myocarditis","volume":"120","author":"Yu","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.critrevonc.2025.104808_bib110","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/ICB.0000000000001413","article-title":"Severe multifocal placoid chorioretinitis associated with immune checkpoint inhibitor therapy","volume":"18","author":"Yu","year":"2024","journal-title":"Retin. Cases Brief. Rep."},{"key":"10.1016\/j.critrevonc.2025.104808_bib111","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1111\/bjd.15237","article-title":"Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors","volume":"176","author":"Zarbo","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.critrevonc.2025.104808_bib112","doi-asserted-by":"crossref","first-page":"8490","DOI":"10.1073\/pnas.1608873113","article-title":"Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model","volume":"113","author":"Zhang","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2025.104808_bib113","article-title":"Immune-related toxic epidermal necrolysis affecting trachea mucosal epithelium: a case report and literature review","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Pharm."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T20:48:35Z","timestamp":1756154915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825001969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":113,"alternative-id":["S1040842825001969"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104808","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T cell-mediated mechanisms of immune-related adverse events induced by immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104808","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104808"}}